This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only.

Background:

The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives.
The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), which mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.

NCATS is in need of fee-for-service pharmacological testing for 15 compounds to detect major potential adverse activity. These services will be used to prioritize "hits" and/or "lead" candidates for further development for several important NCATS projects. The panel should consist of 87 primary molecular targets including 13 enzyme and 74 binding assays.

Purpose and Objectives:

NCATS is in need of fee-for-service pharmacological testing for 15 compounds to detect major potential adverse activity

Project requirements:

Vendor is responsible for providing the following:

• Providing a platform testing that allows to detect major potential adverse activity
• The panel needs to consist of 87 primary molecular target that include 13 enzyme and 74 binding assays; assay list is included
• Vendor must provide primary screening results within two (2) weeks of compound receipt
• Screening against targets should be in duplicate and vendor shall provide results for both enzyme and binding assays
• Batches will be sent in sets of 5 compounds (3 batches of 5 compounds each).
• Batches will be set at varying intervals based on compound performance and synthesis.

Anticipated period of performance:

July 1, 2016 through June 30, 2017.

Capability statement /information sought.

Offerors must provide descriptive literature, warranties, and/or other materials that demonstrate that their offer meets the foregoing requirements. In addition to any of the aforementioned technical/descriptive information, the quoter/offeror shall provide the following information for use in the technical evaluation process:

The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements.

One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing.

The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required.

The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested.

The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses.

All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted.

The response must be submitted to Brian Lind at [email protected]

The response must be received on or before June 30, 2016 at 9:00 AM Eastern Time.

"Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work.

Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation.

Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."